Announces an R&D agreement with Syensqo (2NF.F) (SYENS.BR) to develop its proprietary biological control agent Clonostachys rosea strain CR-7 into a seed treatment formulation for the multi-billion soybean market. “Collaborating with Syensqo is a huge extension of our R&D efforts,” said Ashish Malik, CEO of BVT. “Their large team of formulation chemists and microbiologists will enable us to get to market with a strong seed treatment formulation much faster.” Bee Vectoring Technologies International shares C.BEE are trading unchanged at $0.01.
Stocks in play: Bee Vectoring Technologies International
/A%20Palantir%20sign%20displayed%20on%20an%20office%20building%20by%20Poetra_RH%20via%20Shutterstock.jpg)
/Quantum%20Computing/A%20concept%20image%20showing%20a%20ray%20of%20light%20passing%20through%20cyberspace_%20Image%20by%20metamorworks%20via%20Shutterstock_.jpg)
/Palo%20Alto%20Networks%20Inc%20HQ%20sign-by%20Sundry%20Photography%20via%20Shutterstock.jpg)
/International%20Business%20Machines%20Corp_%20logo%20on%20storage%20rack-by%20Nick%20N%20A%20via%20Shutterstock.jpg)
/AI%20(artificial%20intelligence)/Ai%20chip%20by%20Quality%20Stock%20Arts%20via%20Shutterstock.jpg)